Q&A: Bay­er on­col­o­gy head Chris­tine Roth talks strat­e­gy un­der new CEO

Un­der new CEO Bill An­der­son, Bay­er re­mains com­mit­ted to be­com­ing a top 10 on­col­o­gy play­er, and the road to do­ing so will be paved by key part­ner­ships and progress in prostate and gas­troin­testi­nal can­cers, ex­ec­u­tives said Wednes­day.

That could mean “good-sized” ac­qui­si­tions that hit the com­pa­ny’s “sweet spot” of fo­cus, whether it be a par­tic­u­lar modal­i­ty or pa­tient pop­u­la­tion, said Chris­tine Roth, head of Bay­er’s on­col­o­gy strate­gic busi­ness unit, dur­ing an event at the com­pa­ny’s Re­search and In­no­va­tion Cen­ter in Cam­bridge, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER